High Frequency of Functional Anti-YMDD and -mutant Cytotoxic T Lymphocytes After in Vitro Expansion Correlates with Successful Response to Lamivudine Therapy for Chronic Hepatitis B

Overview

Journal Gut

Specialty Gastroenterology

Date 2004 Dec 14

PMID 15591521

Citations 5

Authors

C-L Lin

S-L Tsai

T-H Lee

R-N Chien

S-K Liao

Y-F Liaw

Affiliations

Soon will be listed here.

Abstract

Background: Many determinants for a sustained response to lamivudine therapy have been reported but the role of T cell responsiveness remains unclear. The finding that tyrosine-methionine-aspartate-aspartate (YMDD) motif of the reverse transcriptase domain of hepatitis B virus (HBV) DNA polymerase carries a HLA-A2 restricted cytotoxic T lymphocyte (CTL) epitope makes quantitative measurement of the numbers of peptide specific CTLs feasible using MHC tetramer-peptide complex staining.

Aim: To investigate the correlation between anti-YMDD motif CTL activity and the efficacy of lamivudine therapy in HLA-A2 positive patients with chronic hepatitis B (CH-B).

Methods: The function and phenotype of peptide and interleukin 2 expanded peripheral blood mononuclear cells were quantified by cell lytic assay and immunocytochemical analysis by staining with HLA-A2-peptide tetramer complexes.

Results: After in vitro expansion, sustained responders had more potent CTL responses against YMDD, YVDD, and YIDD, as well as other epitopes on HBV antigens than non-responders. The frequency of YMDD/YVDD/YIDD motif specific CTLs increased significantly with an effective cell lytic function during and after therapy in sustained responders but not in non-responders. YMDD specific CTLs cross reacted with YIDD and YVDD mutant epitopes, and shared T cell receptor gene usages with YIDD and YVDD specific CTLs.

Conclusions: Sustained responders, at least HLA-A2 patients, elicited a more potent CTL immunity against YMDD and its mutants. YMDD specific CTLs are cross reactive with YVDD and YIDD mutant epitopes, which may further contribute to immune clearance of the mutant viruses and a successful response to lamivudine therapy in CH-B patients.

Citing Articles

Screening and Identification of HBV Epitopes Restricted by Multiple Prevalent HLA-A Allotypes.

Ding Y, Zhou Z, Li X, Zhao C, Jin X, Liu X Front Immunol. 2022; 13:847105.

PMID: 35464415 PMC: 9021956. DOI: 10.3389/fimmu.2022.847105.

A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus.

Wu Y, Ding Y, Shen C Vaccines (Basel). 2022; 10(2).

PMID: 35214714 PMC: 8878595. DOI: 10.3390/vaccines10020257.

Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment.

Kwon S, Choe W, Lee C, Yeon J, Byun K World J Gastroenterol. 2008; 14(27):4416-9.

PMID: 18666338 PMC: 2731201. DOI: 10.3748/wjg.14.4416.

Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot".

Bihl F, Loggi E, Chisholm 3rd J, Hewitt H, Henry L, Linde C J Transl Med. 2005; 3(1):20.

PMID: 15888204 PMC: 1164435. DOI: 10.1186/1479-5876-3-20.

Resistance to lamivudine therapy: is there more than meets the eye?.

Dusheiko G, Bertoletti A Gut. 2004; 54(1):9-10.

PMID: 15591497 PMC: 1774354. DOI: 10.1136/gut.2004.047548.

References

Lauer G, Nguyen T, Day C, Robbins G, Flynn T, McGowan K . Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol. 2002; 76(6):2817-26. PMC: 135971. DOI: 10.1128/jvi.76.6.2817-2826.2002. View

McKenzie R, Fried M, Sallie R, Conjeevaram H, Di Bisceglie A, Park Y . Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995; 333(17):1099-105. DOI: 10.1056/NEJM199510263331702. View

Dienstag J, Cianciara J, Karayalcin S, Kowdley K, Willems B, Plisek S . Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003; 37(4):748-55. DOI: 10.1053/jhep.2003.50117. View

Lee K, Cho S, Kim S, Kim H, Hahm K, Kim J . Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat. 2002; 9(3):208-12. DOI: 10.1046/j.1365-2893.2002.00357.x. View

Lai C, Chien R, Leung N, Chang T, Guan R, Tai D . A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998; 339(2):61-8. DOI: 10.1056/NEJM199807093390201. View

Lauer G, Ouchi K, Chung R, Nguyen T, Day C, Purkis D . Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol. 2002; 76(12):6104-13. PMC: 136241. DOI: 10.1128/jvi.76.12.6104-6113.2002. View

Bertoletti A, Sette A, Chisari F, Penna A, Levrero M, De Carli M . Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature. 1994; 369(6479):407-10. DOI: 10.1038/369407a0. View

Arden B, Clark S, Kabelitz D, Mak T . Human T-cell receptor variable gene segment families. Immunogenetics. 1995; 42(6):455-500. DOI: 10.1007/BF00172176. View

Tsai S, Chen Y, Chen M, Huang C, Sheen I, Yeh C . Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology. 1998; 115(4):954-65. DOI: 10.1016/s0016-5085(98)70268-9. View

10.

Song B, Suh D, Lee H, Chung Y, Lee Y . Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000; 32(4 Pt 1):803-6. DOI: 10.1053/jhep.2000.16665. View

11.

Dienstag J, Schiff E, Mitchell M, Casey Jr D, Gitlin N, Lissoos T . Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology. 1999; 30(4):1082-7. DOI: 10.1002/hep.510300427. View

12.

Allen M, Deslauriers M, Andrews C, Tipples G, Walters K, Tyrrell D . Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998; 27(6):1670-7. DOI: 10.1002/hep.510270628. View

13.

Maini M, Boni C, Ogg G, King A, Reignat S, Lee C . Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology. 1999; 117(6):1386-96. DOI: 10.1016/s0016-5085(99)70289-1. View

14.

Chisari F, Ferrari C . Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995; 13:29-60. DOI: 10.1146/annurev.iy.13.040195.000333. View

15.

Honkoop P, Niesters H, de Man R, Osterhaus A, Schalm S . Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol. 1997; 26(6):1393-5. DOI: 10.1016/s0168-8278(97)80476-x. View

16.

Liaw Y, Chien R, Yeh C, Tsai S, Chu C . Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999; 30(2):567-72. DOI: 10.1002/hep.510300221. View

17.

Chien R, Yeh C, Tsai S, Chu C, Liaw Y . Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003; 38(5):1267-73. DOI: 10.1053/jhep.2003.50458. View

18.

Dienstag J, Schiff E, Wright T, Perrillo R, Hann H, Goodman Z . Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341(17):1256-63. DOI: 10.1056/NEJM199910213411702. View

19.

Maini M, Boni C, Lee C, Larrubia J, Reignat S, Ogg G . The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000; 191(8):1269-80. PMC: 2193131. DOI: 10.1084/jem.191.8.1269. View

20.

Hadziyannis S, Papatheodoridis G, Dimou E, Laras A, Papaioannou C . Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2000; 32(4 Pt 1):847-51. DOI: 10.1053/jhep.2000.17915. View